Thiazolidinediones prevent PDGF-BB-induced CREB depletion in pulmonary artery smooth muscle cells by preventing upregulation of casein kinase 2 α′ catalytic subunit

Journal of Cardiovascular Pharmacology

Volumn 55, Issue 5, 2010, Pages 469-480

  Garat, Chrystelle V ^a   Crossno Jr , Joseph T ^a   Sullivan, Timothy M ^a   Reusch, Jane E B ^a   Klemm, Dwight J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Casein kinase 2; CREB; PDGF BB; Pulmonary artery; Pulmonary hypertension; Smooth muscle cell; Thiazolidinedione

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CASEIN KINASE II; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FASUDIL; PLATELET DERIVED GROWTH FACTOR BB; PROTEIN KINASE B; ROSIGLITAZONE; TROGLITAZONE;

ALPHA CHAIN; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY MUSCLE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME REPRESSION; HYPOXIA; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PULMONARY ARTERY; RAT; SMOOTH MUSCLE FIBER; TISSUE SECTION;

ANIMALS; ANOXIA; BLOTTING, WESTERN; CASEIN KINASE II; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYTOSOL; HYPERTENSION, PULMONARY; MALE; MICROSCOPY, FLUORESCENCE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR; PPAR ALPHA; PULMONARY ARTERY; RATS; RATS, INBRED WKY; THIAZOLIDINEDIONES; UP-REGULATION;

EID: 77952980768     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3181d64dbe     Document Type: Article

References (42)

1. Stenmark KR, McMurtry IF. Vascular remodeling versus vasoconstriction in chronic hypoxic pulmonary hypertension: a time for reappraisal. Circ Res. 2005;97:95-98.
2. Jones R, Jacobson M, Steudel W. A-smooth-muscle actin and microvascular precursor cells in pulmonary hypertension. Am J Respir Cell Mol Biol. 1999;20:582-594.
3. Belknap JK, Orton EC, Ensley B, et al. Hypoxia increase bromodeoxyuridine labeling indices in bovine neonatal pulmonary arteries. Am J Respir Cell Mol Biol. 1997;16:366-371.
4. Cornfield DN, Stevens T, McMurtry IF, et al. Acute hypoxia increases cytosolic calcium in fetal pulmonary artery smooth muscle cells. Am J Physiol. 1993; 265: L53-L56.
5. Salvaterra CG, Goldman WF. Acute hypoxia increases cytosolic calcium in cultured pulmonary arterial myocytes. Am J Physiol. 1993; 264: L323-L328.
6. Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated by mitochondrial complex III stabilize hypoxiainducible factor-1a during hypoxia. J Biol Chem. 2000;275:25130-25138.
7. Herget J, Wilhelm J, Novotna J, et al. A possible role of the oxidant tissue injury in the development of hypoxic pulmonary hypertension. Physiol Res. 2000;49:493-501.
8. Jones RD, Morice AH. Hydrogen peroxide-an intracellular signal in the pulmonary circulation: involvement in hypoxic pulmonary vasoconstriction. Pharmacol Ther. 2000;88:153-161.
9. Killilea DW, Hester R, Balczon R, et al. Free radical production in hypoxic pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L408-L412.
10. Weissman N, Tadic A, Hanze J, et al. Hypoxic vasoconstriction in intact lungs: a role for NADPH oxidase-derived H2O2. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L683-L690.
11. Dawes KE, Peacock AJ, Gray AJ, et al. Characterization of fibroblast mitogens and chemoattractants produced by endothelial cells exposed to hypoxia. Am J Respir Cell Mol Biol. 1994;10:552-559.
12. Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. 1999;26:74-84.
13. Shaul PW, Kinanae B, Farrar MA, et al. Prostacyclin production and mediation of adenylate cyclase activity in the pulmonary artery: alteration after prolonged hypoxia in the rat. J Clin Invest. 1991;88:447-455.
14. Bornfeldt KE, Campbell JS, Koyama H, et al. The mitogen-activated protein kinase pathway can mediate growth inhibition and proliferation in smooth muscle cells. Dependence on the availability of downstrean targets. J Clin Invest. 1997;100:875-885.
15. Graves LM, Bornfeldt KE, Raines EW, et al. Protein kinase A antagonizes platelet-derived growth factor-induced signaling by mitogen-activated protein kinase in human arterial smooth muscle cells. Proc Natl Acad Sci U S A. 1993;90:10300-10304.
16. Vadiveloo PK, Filonzi EL, Stanton HR, et al. G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis. 1997;133:61-69.
17. Hayashi S, Morishita R, Matsushita H, et al. Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. Hypertension. 2000;35:237-243.
18. Klemm DJ, Watson P, Frid MG, et al. cAMP response element-binding protein content is a molecular determinant of smooth muscle cell proliferation and migration. J Biol Chem. 2001;276:46132-46141.
19. Garat C, Fankell D, Erickson PF, et al. PDGF-BB induces nuclear export and proteosomal degradation of CREB via PI3-kinase/Akt signaling in pulmonary artery smooth muscle cells. Mol Cell Biol. 2006;26:4934-4948.
20. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest. 1995;96:354-360.
21. Chen Z, Ishibashi S, Perrey S, et al. Troglitazone inhibits atherosclerosis in apolipoprotein E knockout mice:pleiotropic effects in CD36 expression and HDL. Arterioscler Thromb Vasc Biol. 2001;21:372-377.
22. Collins AR, Meehan WP, Kintscher U, et al. Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:365-371.
23. Jawien A, Bowen-Pope DF, Linder V, et al. Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 1992;89:507-511.
24. Koshiyama H, Shimono D, Kuwamura N, et al. Rapid communication: inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab. 2001;86:3452-3456.
25. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intimal-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111:2525-2531.
26. Law RE, Meehan WP, Xi XP, et al. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest. 1996;98:1897-1905.
27. Crossno JT Jr., Garat CV, Reusch JE, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007; 292: L885-L897.
28. Watson P, Nesterova A, Burant CF, et al. Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. J Biol Chem. 2001;276:46142-46150.
29. Crossno JT Jr, Garat CV, Reusch JE, et al. Rosiglitazone attenuates hypoxia-induced pulmonary artery remodeling. Am J Physiol Lung Cell Mol Physiol. 2006. [Epub ahead of print].
30. Matsuda Y, Hoshikawa Y, Ameshima S, et al. Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats. Nihon Kokyuki Gakkai Zasshi. 2005;43:283-288.
31. Hansmann G, Wagner RA, Schellong S, et al. Pulmonary arterial hypertensions linked to insulin resistance and reversed by peroxisome proliferatoractivated receptor-gamma activation. Circulation. 2006;115:1275-1284.
32. Litchfield DW. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J. 2003;369:1-15.
33. Pyerin W, Ackermann K. Transcriptional coordination of the genes encoding catalytic (CK2alpha) and regulatory (CK2beta) subunits of human protein kinase CK2. Mol Cell Biochem. 2001;227:45-57.
34. Gapany M, Faust RA, Tawfic S, et al. Association of elevated protein kinase Ck2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med. 1995;1:659-666.
35. Munsterman U, Fritz G, Seitz G, et al. Casein kinase II is elevated in solid human tumors and rapidly proliferating neoplastic tissue. Eur J Biochem. 1990;180:251-257.
36. Ryu S-W, Woo JH, Kim Y-H, et al. Down-regulation of protein kinase CKII is associated with cellular senescence. FEBS Lett. 2006;580:988-994.
37. Pepperkok R, Lorenz P, Ansorge W, et al. Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem. 1994;269:6986-6991.
38. Pepperkok R, Lorenz P, Jakobi R, et al. Cell growth stimulation by EGF: inhibition through antisense oligodeoxynucleotides demonstrates important role of casein kinase II. Exp Cell Res. 1991;197:245-253.
39. Lebrin F, Chambaz EM, Bianchini L. A role for protein kinase CK2 in cell proliferation: evidence using a kinase-inactive mutant of CK2 catalytic subunit alpha. Oncogene. 2001;20:2010-2022.
40. Xu X, Landesman-Bollag E, Channavajhala PL, et al. Murine protein kinase CK2: Gene and oncogene. Mol Cell Biochem. 1999;191:65-74.
41. Krehan A, Ansuini H, Bocher O, et al. Transcription factors Ets1, NFkappaB and Sp1 are major determinants of the promoter activity of the human protein kinase CK2 gene. J Biol Chem. 2000;275:18327-18336.
42. Kim E-Y, Kang J-Y, Rho Y-H, et al. Silencing of the CKIIalpha and CKIIalpha' genes during cellular senescence is mediated by DNA methylation. Gene. 2009;431:55-60.